Literature DB >> 18347536

Human myoblast engraftment is improved in laminin-enriched microenvironment.

Suse D Silva-Barbosa1, Gillian S Butler-Browne, Wallace de Mello, Ingo Riederer, James P Di Santo, Wilson Savino, Vincent Mouly.   

Abstract

BACKGROUND: One major challenge in developing cell therapy for muscle diseases is to define the best condition for the recipient's muscle to niche donor cells. We have examined the efficiency of human myoblast transplantation in an immunodeficient animal model, after local irradiation, as well as the potential impact of laminin on myoblast behavior.
METHODS: Human myoblasts were injected into preirradiated tibialis anterior muscles from immunodeficient mice. The donor cell engraftment, proliferation, and laminin content within the transplanted muscles were evaluated by immunocytochemistry. Additionally, the effect of laminin upon myoblast proliferation, migration, and survival was ascertained in vitro.
RESULTS: Engraftment of human myoblasts into the skeletal muscle of immunodeficient Rag2-/gammac-/C5- mice presubjected to local irradiation provided the best niche for myoblast engraftment, as demonstrated by the number of viable and proliferating donor cells found in the host muscle. Local irradiation significantly enhanced laminin deposition within the recipient's muscle and donor cells were preferentially located in laminin-enriched areas. The same batch of myoblasts used for in vivo injections also responded to laminin in vitro with increased proliferation and cell survival, as well as an improved migratory response.
CONCLUSIONS: We show that local irradiation enhances the laminin content in the host muscle microenvironment and provides a better engraftment of human myoblasts. In addition, laminin increases myoblast proliferation, survival, and migration in vitro. These data provide combined in vivo and in vitro evidence that laminin status should be taken into account when designing experimental and clinical cell therapy strategies for muscle disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18347536     DOI: 10.1097/TP.0b013e31815fee50

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  21 in total

1.  Slowing down differentiation of engrafted human myoblasts into immunodeficient mice correlates with increased proliferation and migration.

Authors:  Ingo Riederer; Elisa Negroni; Maximilien Bencze; Annie Wolff; Ahmed Aamiri; James P Di Santo; Suse D Silva-Barbosa; Gillian Butler-Browne; Wilson Savino; Vincent Mouly
Journal:  Mol Ther       Date:  2011-09-20       Impact factor: 11.454

Review 2.  Are human and mouse satellite cells really the same?

Authors:  Luisa Boldrin; Francesco Muntoni; Jennifer E Morgan
Journal:  J Histochem Cytochem       Date:  2010-07-19       Impact factor: 2.479

3.  Laminin-111: a potential therapeutic agent for Duchenne muscular dystrophy.

Authors:  Sébastien Goudenege; Yann Lamarre; Nicolas Dumont; Joël Rousseau; Jérôme Frenette; Daniel Skuk; Jacques P Tremblay
Journal:  Mol Ther       Date:  2010-08-03       Impact factor: 11.454

4.  Laminin-111 improves skeletal muscle stem cell quantity and function following eccentric exercise.

Authors:  Kai Zou; Michael De Lisio; Heather D Huntsman; Yair Pincu; Ziad Mahmassani; Matthew Miller; Dami Olatunbosun; Tor Jensen; Marni D Boppart
Journal:  Stem Cells Transl Med       Date:  2014-07-10       Impact factor: 6.940

5.  MMP-14 is necessary but not sufficient for invasion of three-dimensional collagen by human muscle satellite cells.

Authors:  Dane K Lund; Vincent Mouly; D D W Cornelison
Journal:  Am J Physiol Cell Physiol       Date:  2014-06-04       Impact factor: 4.249

Review 6.  Multiplicity of experimental approaches to therapy for genetic muscle diseases and necessity for population screening.

Authors:  Nigel G Laing
Journal:  J Muscle Res Cell Motil       Date:  2008-12-30       Impact factor: 2.698

7.  The Rag2⁻Il2rb⁻Dmd⁻ mouse: a novel dystrophic and immunodeficient model to assess innovating therapeutic strategies for muscular dystrophies.

Authors:  Denis Vallese; Elisa Negroni; Stéphanie Duguez; Arnaud Ferry; Capucine Trollet; Ahmed Aamiri; Christian A J Vosshenrich; Ernst-Martin Füchtbauer; James P Di Santo; Libero Vitiello; Gillian Butler-Browne; Vincent Mouly
Journal:  Mol Ther       Date:  2013-08-23       Impact factor: 11.454

8.  The effect of the muscle environment on the regenerative capacity of human skeletal muscle stem cells.

Authors:  Jinhong Meng; Maximilien Bencze; Rowan Asfahani; Francesco Muntoni; Jennifer E Morgan
Journal:  Skelet Muscle       Date:  2015-04-28       Impact factor: 4.912

9.  CD49d is a disease progression biomarker and a potential target for immunotherapy in Duchenne muscular dystrophy.

Authors:  Fernanda Pinto-Mariz; Luciana Rodrigues Carvalho; Alexandra Prufer De Queiroz Campos Araujo; Wallace De Mello; Márcia Gonçalves Ribeiro; Maria Do Carmo Soares Alves Cunha; Pedro Hernan Cabello; Ingo Riederer; Elisa Negroni; Isabelle Desguerre; Mariana Veras; Erica Yada; Yves Allenbach; Olivier Benveniste; Thomas Voit; Vincent Mouly; Suse Dayse Silva-Barbosa; Gillian Butler-Browne; Wilson Savino
Journal:  Skelet Muscle       Date:  2015-12-10       Impact factor: 4.912

10.  Defects in glycosylation impair satellite stem cell function and niche composition in the muscles of the dystrophic Large(myd) mouse.

Authors:  Jacob Ross; Abigail Benn; Jacqueline Jonuschies; Luisa Boldrin; Francesco Muntoni; Jane E Hewitt; Susan C Brown; Jennifer E Morgan
Journal:  Stem Cells       Date:  2012-10       Impact factor: 6.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.